Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Malignant Melanoma

  Free Subscription


1 Am J Dermatopathol
1 Ann Surg Oncol
1 BMC Cancer
1 Br J Dermatol
1 Int J Cancer
1 J Am Acad Dermatol
1 J Cell Physiol
1 J Immunother
1 Lancet Child Adolesc Health
1 Lancet Oncol
1 Melanoma Res
1 Nat Rev Cancer

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Dermatopathol

  1. HUI ONG EL, Sinha R, Jmor S, Fearfield L, et al
    BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
    Am J Dermatopathol. 2018 Dec 21. doi: 10.1097/DAD.0000000000001276.
    PubMed     Text format     Abstract available

    Ann Surg Oncol

  2. MAHVI DA, Fairweather M, Yoon CH, Cho NL, et al
    Utility of Level III Axillary Node Dissection in Melanoma Patients with Palpable Axillary Lymph Node Disease.
    Ann Surg Oncol. 2019 Jun 17. pii: 10.1245/s10434-019-07509.
    PubMed     Text format     Abstract available

    BMC Cancer

  3. XU M, Wang X, Pan Y, Zhao X, et al
    Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    BMC Cancer. 2019;19:599.
    PubMed     Text format     Abstract available

    Br J Dermatol

  4. LIYANAGE UE, Law MH, Barrett JH, Iles MM, et al
    Is there a causal relationship between vitamin D and melanoma risk? : A Mendelian randomization study.
    Br J Dermatol. 2019 Jun 19. doi: 10.1111/bjd.18238.
    PubMed     Text format     Abstract available

    Int J Cancer

  5. GENER LAHAV T, Adler O, Zait Y, Shani O, et al
    Melanoma-derived extracellular vesicles instigate pro-inflammatory signaling in the metastatic microenvironment.
    Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32521.
    PubMed     Text format     Abstract available

    J Am Acad Dermatol

  6. JO G, Cho SI, Choi S, Mun JH, et al
    Functional surgery versus amputation for in situ or minimally invasive nail melanoma: A meta-analysis.
    J Am Acad Dermatol. 2019 Jun 13. pii: S0190-9622(19)30975.
    PubMed     Text format     Abstract available

    J Cell Physiol

  7. MO Y, Fang RH, Wu J, Si Y, et al
    MicroRNA-329 upregulation impairs the HMGB2/beta-catenin pathway and regulates cell biological behaviors in melanoma.
    J Cell Physiol. 2019 Jun 20. doi: 10.1002/jcp.28920.
    PubMed     Text format     Abstract available

    J Immunother

  8. KHOURY ZH, Hausner PF, Idzik-Starr CL, Frykenberg MRA, et al
    Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
    J Immunother. 2019 Jun 14. doi: 10.1097/CJI.0000000000000282.
    PubMed     Text format     Abstract available

    Lancet Child Adolesc Health

  9. MERKEL EA, Mohan LS, Shi K, Panah E, et al
    Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis.
    Lancet Child Adolesc Health. 2019 Jun 13. pii: S2352-4642(19)30116.
    PubMed     Text format     Abstract available

    Lancet Oncol

  10. LONG GV, Dummer R, Hamid O, Gajewski TF, et al
    Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30274.
    PubMed     Text format     Abstract available

    Melanoma Res

  11. ANDERSON KL, Snyder KM, Ito D, Lins DC, et al
    Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
    Melanoma Res. 2019 Jun 12. doi: 10.1097/CMR.0000000000000629.
    PubMed     Text format     Abstract available

    Nat Rev Cancer

  12. AROZARENA I, Wellbrock C
    Phenotype plasticity as enabler of melanoma progression and therapy resistance.
    Nat Rev Cancer. 2019 Jun 17. pii: 10.1038/s41568-019-0154.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.